Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce it assisted the successful completion of a transaction in which Vendis Capital, a European private equity fund specialized in the consumer brands sector, invested in Sylphar, a fast-growing, Belgian consumer healthcare company having a portfolio of brands in the oral beauty, oral therapy and medicated skincare market segments. The Vendis Capital investment enabled Concordia Fund, a long-time investor in Sylphar, to exit.
Sylphar Founder and CEO, Robin List, commented: “Thanks to the hard work of the team, we have built a solid track record of success so far, but I’m convinced there is still much to be done. We have indeed the ambition to build a portfolio of a small number of strategic niche brands that will have a leading position in their respective category and geographies, be it organically or through acquisitions. We believe Vendis is the right partner to help us achieve that goal.”
Bob Moran, Plexus Ventures’ President noted: “Robin List and a capable management team at Sylphar have succeeded in developing exciting and innovative new brands. We believe Vendis Capital is uniquely positioned to help Sylphar grow both organically and through strategic acquisitions. We wish all involved much success going forward.”
About Sylphar (sylphar.com)
Sylphar is a Belgium-based company developing and marketing OTC products worldwide. The company offers teeth whitening products under the leading brand iWhite, an innovative range of solutions for specific skin conditions under the Remescar brand, and oral therapeutics under the Herpatch (cold sores and ulcers) and Shur (bad breath) brands. With sales all over the world, the major markets of the company include Spain, UK, Germany, France, Italy and Eastern countries.
